FDA supplemental approval: Mycophenolate Sodium (REMS)

AI Summary

This is a regulatory approval record documenting FDA authorization of a supplemental Risk Evaluation and Mitigation Strategy (REMS) for mycophenolate sodium (delayed-release tablets in 180 mg and 360 mg formulations) manufactured by Teva Pharmaceuticals USA, approved on 29 July 2026. The record itself contains no clinical trial results, efficacy data, or outcome measures; it reflects FDA's determination that a REMS is necessary for safe use of this product.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for an existing immunosuppressant; indicates regulatory action on safety management, not new clinical efficacy evidence.

Study design

As stated by the source record.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

Clinicians should be aware that mycophenolate sodium use is subject to an FDA-mandated REMS. The record does not provide clinical trial data, efficacy information, or details of the REMS requirements; refer to the full REMS document and product labeling for prescribing guidance and risk mitigation obligations.

Caveats

• This regulatory record contains no clinical trial data, efficacy results, or safety outcomes.
• The specific elements and objectives of the approved REMS are not described in this submission record.
• No comparator arm, control group, or statistical analyses are provided.
• The record does not establish or report clinical indications, dosing, or clinical efficacy for mycophenolate sodium.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.